GenomeWeb

NEW YORK – The parent of an Invitae patient has brought a class action complaint against Laboratory Corporation of America's Invitae business, alleging that it illegally disclosed the genetic information of tens of thousands of individuals when it sold certain of its assets to Labcorp in 2024.

NEW YORK – In a decision handed down on Tuesday by the US District Court for the District of Delaware, Guardant Health dodged trebled damages in a patent infringement case involving TwinStrand Biosciences and the University of Washington, However, Guardant's motion for judgment as a matter of law or a new trial was denied, and TwinStrand was awarded a request for ongoing royalties at an ongoing royalty rate of 6 percent.

NEW YORK – The American College of Medical Genetics and Genomics (ACMG) has published new recommendations for improving how variants of unknown significance (VUS) are reported in light of the ACMG's new variant subclassification system. The organization also published new guidance to facilitate a better understanding of testing repeat expansions via next-generation sequencing. The recommendations appear in two Points to Consider statements, both published last week in Genetics in Medicine.

NEW YORK – Researchers are advancing a tissue and liquid biopsy-based tool for pleural mesothelioma patients that uses DNA methylation status to predict their outcomes on standard immunotherapy treatments. Research detailing the identification of methylation subgroups in mesothelioma and the development of the tool was published in May in Nature Genetics.

NEW YORK – Ménière disease (MD), a chronic inner ear condition, may stem in part from genetic alterations affecting inner ear development, according to a new study. The disorder, which is marked by symptoms such as tinnitus, recurrent bouts of severe vertigo, and fluctuating sensorineural hearing loss, often overlaps with an endolymphatic hydrops condition in which fluid accumulates in the inner ear.

NEW YORK – Adaptive Biotechnologies said on Monday after market close that it plans to separate its minimal residual disease (MRD) and immune medicine businesses, with the goal to identify the "preferred path to separation" by the end of the year. The Seattle-based company also separately said it plans to offer $250 million aggregate principal amount of convertible senior notes due 2031 to qualified private institutional buyers.

NEW YORK — Inflammatix said on Tuesday that it has begun exploring the use of its point-of-care TriVerity immune response test to detect hantaviruses in collaboration with the University of Nebraska Medical Center (UNMC). TriVerity is a blood-based reverse transcription loop-mediated isothermal amplification assay that runs on Inflammatix's cartridge-based Myrna instrument and uses machine learning to gauge a panel of 29 mRNA biomarkers to assess a patient's immune response to infection.

NEW YORK – Autonomous Medical Devices Incorporated (AMDI) has obtained 510(k) clearance and CLIA waiver from the US Food and Drug Administration for its Fast PCR system and a syndromic respiratory panel, the firm announced on Tuesday.

GOTHENBURG, Sweden – Illumina on Monday announced the launch of a new study, in partnership with centers in Europe and the Middle East, that aims to increase the number of diagnoses for children with rare diseases who underwent rapid whole-genome sequencing when they were in neonatal or pediatric intensive care but whose cases remain unsolved.

NEW YORK – Adaptive Biotechnologies said on Monday after market close that it plans to separate its minimal residual disease (MRD) and immune medicine businesses, with the goal to identify the "preferred path to separation" by the end of the year. The Seattle-based company also separately said it plans to offer $250 million aggregate principal amount of convertible senior notes due 2031 to qualified private institutional buyers.